Health Tidings Mergers & AcquisitionsAscidian Bets on Exegenesis to Optimize AAV Delivery for RNA Exon Editors Ascidian Bets on Exegenesis to Optimize AAV Delivery for RNA Exon Editors Read Post »
Health Tidings Mergers & AcquisitionsPfizer Advances Berobenatide With $1.5B Blackstone Deal Pfizer Advances Berobenatide With $1.5B Blackstone Deal Read Post »
Health Tidings Mergers & Acquisitionsargenx to Acquire UNP, Adding a New Molecular Discovery Platform argenx to Acquire UNP, Adding a New Molecular Discovery Platform Read Post »
Health Tidings Mergers & AcquisitionsBoehringer Ingelheim and China’s Sino Strike $7.4B Oncology Deal Boehringer Ingelheim and China’s Sino Strike $7.4B Oncology Deal Read Post »
Health Tidings Mergers & AcquisitionsEvommune Bets on EVO570 and VAV1 Degradation with $1.1B Hinova Deal Evommune Bets on EVO570 and VAV1 Degradation with $1.1B Hinova Deal Read Post »
Health Tidings Mergers & AcquisitionsNxera Licenses IBD Candidate to AbbVie in $1.47B Deal Nxera Licenses IBD Candidate to AbbVie in $1.47B Deal Read Post »
Health Tidings Mergers & AcquisitionsBrise Reports Milestone Progress in $757M AbbVie Migraine Deal Brise Reports Milestone Progress in $757M AbbVie Migraine Deal Read Post »
Health Tidings Mergers & AcquisitionsFresenius Extends Biopharma Growth Beyond 2030 With WuXi Deal Fresenius Extends Biopharma Growth Beyond 2030 With WuXi Deal Read Post »
Health Tidings Mergers & AcquisitionsBioMarin, GC Biopharma and Hanmi Pharm Sign $475M Fabry Therapy Deal BioMarin, GC Biopharma and Hanmi Pharm Sign $475M Fabry Therapy Deal Read Post »
Health Tidings Mergers & AcquisitionsNovocure to Evaluate TTFields With Verastem’s VS-7375 in Pancreatic Cance... Novocure to Evaluate TTFields With Verastem’s VS-7375 in Pancreatic Cance... Read Post »
Health Tidings Mergers & AcquisitionsAstellas and Audax Sign US$1.34 Billion Agreement for DAX-044 Astellas and Audax Sign US$1.34 Billion Agreement for DAX-044 Read Post »
Health Tidings Mergers & AcquisitionsTeva Acquires BXCL501, Targeting At-Home Agitation Care Teva Acquires BXCL501, Targeting At-Home Agitation Care Read Post »
Health Tidings Mergers & AcquisitionsRumi Advances PDE2 Inhibitor RTX-7340 for Fragile X Syndrome Rumi Advances PDE2 Inhibitor RTX-7340 for Fragile X Syndrome Read Post »
Health Tidings Mergers & AcquisitionsIncyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Incyte, Genmab Partner on KRAS G12D Colorectal Cancer Trial Read Post »
Health Tidings Mergers & AcquisitionsZymeworks Grants Roche Global Rights to ZW209 in $813M Deal Zymeworks Grants Roche Global Rights to ZW209 in $813M Deal Read Post »
Health Tidings Mergers & AcquisitionsMenarini Bets on Georgiamune’s GIM-621 With $1.1B Deal Menarini Bets on Georgiamune’s GIM-621 With $1.1B Deal Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca, Oracle Link Real-World Data With Clinical Research AstraZeneca, Oracle Link Real-World Data With Clinical Research Read Post »
Health Tidings Mergers & AcquisitionsHansoh Expands Roche ADC Deal With $15B+ in Potential Milestones Hansoh Expands Roche ADC Deal With $15B+ in Potential Milestones Read Post »
Health Tidings Mergers & AcquisitionsAdlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Adlai Nortye Partners with Eli Lilly and Merck KGaA for Phase I ADC Combina... Read Post »
Health Tidings Mergers & AcquisitionsEton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Eton Secures U.S. Rights to LIBERVANT Seizure Rescue Film Read Post »
Health Tidings Mergers & AcquisitionsGenerate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Generate Signs $1.2B Milestone Deal with Zealand for AI-Designed Protein Dr... Read Post »
Health Tidings Mergers & AcquisitionsPrelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Prelude and Lilly Partner to Test PRT13722 Combinations in HR+/HER2− Brea... Read Post »
Health Tidings Mergers & AcquisitionsRoche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Roche and Rona Sign $1.16B Deal for ALK7-Targeting RNAi Obesity Candidate Read Post »
Health Tidings Mergers & AcquisitionsViatris to Acquire Pacira for $1.65 Billion Viatris to Acquire Pacira for $1.65 Billion Read Post »
Health Tidings Mergers & AcquisitionsShionogi Plans $2 Billion Acquisition of IntraBio to Expand Rare Disease Po... Shionogi Plans $2 Billion Acquisition of IntraBio to Expand Rare Disease Po... Read Post »
Health Tidings Mergers & AcquisitionsAlector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Alector Signs $1.27 Billion Genentech Deal for Parkinson’s Disease Therap... Read Post »
Health Tidings Mergers & AcquisitionsCSL and Alentis Partner to Advance Lixudebart in Kidney and Liver Diseases CSL and Alentis Partner to Advance Lixudebart in Kidney and Liver Diseases Read Post »
Mergers & AcquisitionsSernova and Seraxis Close $11.2 Million Financing to Advance BetaNova’s T... Sernova and Seraxis Close $11.2 Million Financing to Advance BetaNova’s T... Read Post »
Health Tidings Mergers & AcquisitionsAbogen and Novartis Partner to Advance mRNA-Encoded T-Cell Engager ABO2203 Abogen and Novartis Partner to Advance mRNA-Encoded T-Cell Engager ABO2203 Read Post »
Health Tidings Mergers & AcquisitionsItalfarmaco, JCR Sign JR-141 Licensing Deal for Hunter Syndrome Italfarmaco, JCR Sign JR-141 Licensing Deal for Hunter Syndrome Read Post »
Health Tidings Mergers & AcquisitionsRegeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Regeneron and Sanofi Expand Immunology Deal to $8B With Four Long-Acting An... Read Post »
Health Tidings Mergers & AcquisitionsAstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... AstraZeneca Invests $2 Billion in Summit to Advance Ivonescimab-ADC Combina... Read Post »
Health Tidings Mergers & AcquisitionsNovo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Novo Secures Global Rights to Hengrui’s Once-Weekly Oral GLP-1/GIP Agonis... Read Post »
Health Tidings Mergers & AcquisitionsMerck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Merck and SciBrunch Sign $2.13 Billion Deal for KRAS G12D Inhibitor SPR2015 Read Post »
Health Tidings Mergers & AcquisitionsHenlius, Amberstone Develop Tumor-Activated TCEs for Solid Tumors Henlius, Amberstone Develop Tumor-Activated TCEs for Solid Tumors Read Post »
Health Tidings Mergers & AcquisitionsAtavistik Bio, Roche Partner on Allosteric CVRM Drugs Atavistik Bio, Roche Partner on Allosteric CVRM Drugs Read Post »
Health Tidings Mergers & AcquisitionsLexeo Expands Friedreich Ataxia Pipeline With Mantle Acquisition Lexeo Expands Friedreich Ataxia Pipeline With Mantle Acquisition Read Post »
Health Tidings Mergers & AcquisitionsEnvisagenics, Boehringer Partner on RNA Splicing Cancer Targets Envisagenics, Boehringer Partner on RNA Splicing Cancer Targets Read Post »
Health Tidings Mergers & AcquisitionsAbbVie and Iambic Partner to Accelerate AI-Driven Small-Molecule Drug Disco... AbbVie and Iambic Partner to Accelerate AI-Driven Small-Molecule Drug Disco... Read Post »
Health Tidings Mergers & AcquisitionsTelix to Acquire ITM in $1.65 Billion Radiopharmaceutical Deal Telix to Acquire ITM in $1.65 Billion Radiopharmaceutical Deal Read Post »
Mergers & Acquisitions1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals 1ST-104 Parkinson’s Drug Licensed by SK Biopharmaceuticals Read Post »
Health Tidings Mergers & AcquisitionsRoche, Dualitas Launch Bispecific Antibody Discovery Deal Roche, Dualitas Launch Bispecific Antibody Discovery Deal Read Post »
Health Tidings Mergers & AcquisitionsLisata Acquires Marea, Raises $225M for Cardioendocrine Drug Development Lisata Acquires Marea, Raises $225M for Cardioendocrine Drug Development Read Post »
Health Tidings Mergers & AcquisitionsNovo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug Discovery Novo Nordisk and Anthropic Partner to Accelerate AI-Driven Drug Discovery Read Post »
Health Tidings Mergers & AcquisitionsGSK to Acquire Chimagen’s Trispecific T-Cell Engager for Multiple Myeloma GSK to Acquire Chimagen’s Trispecific T-Cell Engager for Multiple Myeloma Read Post »
Health Tidings Mergers & AcquisitionsHUTCHMED Licenses KRAS-EGFR Therapy to GSK in $1.3 Billion Deal HUTCHMED Licenses KRAS-EGFR Therapy to GSK in $1.3 Billion Deal Read Post »
Health Tidings Mergers & AcquisitionsDualityBio, Genentech Strike ADC Deal Worth More Than $1 Billion in Potenti... DualityBio, Genentech Strike ADC Deal Worth More Than $1 Billion in Potenti... Read Post »
Health Tidings Mergers & AcquisitionsMcKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding C... McKesson to Acquire Precision Medicine Group for $2.25 Billion, Expanding C... Read Post »
Health Tidings Mergers & AcquisitionsHanmi Pharm Signs Up to $2.3 Billion Genentech Deal for Obesity Candidate H... Hanmi Pharm Signs Up to $2.3 Billion Genentech Deal for Obesity Candidate H... Read Post »
Health Tidings Mergers & AcquisitionsWerewolf Therapeutics and Ambros Therapeutics Merge to Advance Neridronate ... Werewolf Therapeutics and Ambros Therapeutics Merge to Advance Neridronate ... Read Post »
